Abiraterone in Prostate Cancer

Clinical Cancer Research, 04/06/2012

Abiraterone's efficacy shows the importance of androgen signaling in patients with castrate–resistant metastatic disease, with additional confirmation from recent studies of other novel agents such as MDV3100, an androgen receptor signaling inhibitor.

Print Article Summary